PURPOSE: To examine the practice patterns and predictors of VTE prophylaxis following radical prostatectomy (RP). METHODS: This was a population-based observational study of 94,709 men with a diagnosis of prostate cancer (ICD-9 code 185) who underwent RP were identified from a hospital-based database from 2000 to 2010, including 68,244 (72.1 %) open RP (ORP) and 26,465 (27.9 %) robotic-assisted laparoscopic RP (RALP). VTE prophylaxis was classified as none, mechanical, pharmacologic, or combination. RESULTS: Following RP, 35,591 (52.2 %) received mechanical, 4,945 (7.2 %) pharmacologic, 7,720 (10.6 %) combination, and 20,438 (30.0 %) no VTE prophylaxis. A total of 245 VTE events (145 DVT, 114 PE) were identified, representing 0.25 % of all procedures. Men with >2 comorbidities (OR = 2.44; 95 % CI 1.78-3.35) and those who were black (OR = 1.44; 95 % CI 1.06-1.97) were more likely to have a VTE. Men who had RALP (OR = 0.61; 95 % CI 0.45-0.99), surgery at high-volume hospitals (OR = 0.45; 95 % CI 0.28-0.73), or received prophylaxis (OR = 0.67; 95 % CI 0.50-0.88) were less likely to develop a VTE. CONCLUSION: Despite the observation that VTE prophylaxis reduces the risk of VTE by 40 %, VTE prophylaxis was not used in almost one-third of men who underwent radical prostatectomy.
PURPOSE: To examine the practice patterns and predictors of VTE prophylaxis following radical prostatectomy (RP). METHODS: This was a population-based observational study of 94,709 men with a diagnosis of prostate cancer (ICD-9 code 185) who underwent RP were identified from a hospital-based database from 2000 to 2010, including 68,244 (72.1 %) open RP (ORP) and 26,465 (27.9 %) robotic-assisted laparoscopic RP (RALP). VTE prophylaxis was classified as none, mechanical, pharmacologic, or combination. RESULTS: Following RP, 35,591 (52.2 %) received mechanical, 4,945 (7.2 %) pharmacologic, 7,720 (10.6 %) combination, and 20,438 (30.0 %) no VTE prophylaxis. A total of 245 VTE events (145 DVT, 114 PE) were identified, representing 0.25 % of all procedures. Men with >2 comorbidities (OR = 2.44; 95 % CI 1.78-3.35) and those who were black (OR = 1.44; 95 % CI 1.06-1.97) were more likely to have a VTE. Men who had RALP (OR = 0.61; 95 % CI 0.45-0.99), surgery at high-volume hospitals (OR = 0.45; 95 % CI 0.28-0.73), or received prophylaxis (OR = 0.67; 95 % CI 0.50-0.88) were less likely to develop a VTE. CONCLUSION: Despite the observation that VTE prophylaxis reduces the risk of VTE by 40 %, VTE prophylaxis was not used in almost one-third of men who underwent radical prostatectomy.
Authors: Michael B Rothberg; Penelope S Pekow; Maureen Lahti; Oren Brody; Daniel J Skiest; Peter K Lindenauer Journal: JAMA Date: 2010-05-26 Impact factor: 56.272
Authors: Gordon H Guyatt; John W Eikelboom; Michael K Gould; David A Garcia; Mark Crowther; M Hassan Murad; Susan R Kahn; Yngve Falck-Ytter; Charles W Francis; Maarten G Lansberg; Elie A Akl; Jack Hirsh Journal: Chest Date: 2012-02 Impact factor: 9.410
Authors: Francesco Montorsi; Timothy G Wilson; Raymond C Rosen; Thomas E Ahlering; Walter Artibani; Peter R Carroll; Anthony Costello; James A Eastham; Vincenzo Ficarra; Giorgio Guazzoni; Mani Menon; Giacomo Novara; Vipul R Patel; Jens-Uwe Stolzenburg; Henk Van der Poel; Hein Van Poppel; Alexandre Mottrie Journal: Eur Urol Date: 2012-06-07 Impact factor: 20.096
Authors: Jason D Wright; Sharyn N Lewin; Monjri Shah; William M Burke; Shing M Lee; Xuming Sun; Thomas J Herzog Journal: Ann Surg Date: 2011-06 Impact factor: 12.969
Authors: Jason D Wright; Cande V Ananth; Sharyn N Lewin; William M Burke; Yu-Shiang Lu; Alfred I Neugut; Thomas J Herzog; Dawn L Hershman Journal: JAMA Date: 2013-02-20 Impact factor: 56.272
Authors: Fernando P Secin; Thomas Jiborn; Anders S Bjartell; Georges Fournier; Laurent Salomon; Clément Claude Abbou; George P Haber; Inderbir S Gill; Laura E Crocitto; Rebecca A Nelson; José R Cansino Alcaide; Luis Martínez-Piñeiro; Michael S Cohen; Ingolf Tuerk; Claude Schulman; Troy Gianduzzo; Christopher Eden; Roxelyn Baumgartner; Joseph A Smith; Kim Entezari; Roland van Velthoven; Gunter Janetschek; Angel M Serio; Andrew J Vickers; Karim Touijer; Bertrand Guillonneau Journal: Eur Urol Date: 2007-06-11 Impact factor: 20.096
Authors: Jim C Hu; Xiangmei Gu; Stuart R Lipsitz; Michael J Barry; Anthony V D'Amico; Aaron C Weinberg; Nancy L Keating Journal: JAMA Date: 2009-10-14 Impact factor: 56.272
Authors: Alok A Khorana; Michael B Streiff; Dominique Farge; Mario Mandala; Philippe Debourdeau; Francis Cajfinger; Michel Marty; Anna Falanga; Gary H Lyman Journal: J Clin Oncol Date: 2009-08-31 Impact factor: 44.544
Authors: Wojciech Michalski; Grazyna Poniatowska; Joanna Jonska-Gmyrek; Jakub Kucharz; Pawel Stelmasiak; Karol Nietupski; Katarzyna Ossolinska-Skurczynska; Michal Sobieszczuk; Tomasz Demkow; Pawel Wiechno Journal: Med Oncol Date: 2019-11-25 Impact factor: 3.064
Authors: Lars Lund; Harry Nisen; Petrus Järvinen; Magnus Fovaeus; Eirikur Gudmundsson; Bjarne Kromann-Andersen; Börje Ljungberg; Frode Nilsen; Pernilla Sundqvist; Peter E Clark; Christian Beisland Journal: Res Rep Urol Date: 2018-10-25
Authors: Adam Ostrowski; Piotr Skrudlik; Filip Kowalski; Paweł Lipowski; Magdalena Ostrowska; Przemysław Adamczyk; Jan Adamowicz; Tomasz Drewa; Kajetan Juszczak Journal: Cent European J Urol Date: 2022-04-14